The melanoma differentiation-associated gene-7 (mda-7) is a member of the interleukin-10 cytokine family and a novel tumor suppressor gene. Adenoviral-mediated mda-7 (Ad-mda7) gene transfer has tumor-specific growth inhibitory and proapoptotic effects in a broad spectrum of cancer cells. In breast cancer cells, adenoviral-induced mda-7 expression triggers antiproliferative effects by downregulation of survival signals, such as Bcl-2 and Akt. The anti-human epidermal growth factor receptor-2 (Her-2) monoclonal antibody, Trastuzumab (Herceptin), increases the sensitivity of Her-2/neu-overexpressing breast cancer cells to chemotherapeutic agents and radiotherapy. In this study, we evaluate the effects of treatment with Ad-mda7 and Herceptin combination therapy in a panel of Her-2/neu-overexpressing cell lines, and in established tumors in nude mice. Compared to individual treatments, the combination of Ad-mda7 and Herceptin elicits supra-additive antitumor activity in Her-2/neuoverexpressing tumor cell lines: increased cell death, cell cycle block and apoptosis. The Ad-mda7 and Herceptin interaction was shown to be synergistic by isobologram analysis. Ad-mda7 does not alter cell surface Her-2/neu levels, but the combination of Ad-mda7 þ Herceptin results in increased expression of cell surface E-cadherin with concomitant translocation of b-catenin from the nucleus to the cell membrane. In vivo, the combination of Ad-mda7 and Herceptin showed significantly increased antitumor activity (Po0.003) against Her-2/neu-overexpressing tumors. These data suggest that the combination of Ad-mda7 with Herceptin may be a novel therapy for breast cancer patients whose tumors overexpress Her-2/neu. The observed synergistic effect may improve treatment options for otherwise poorly responsive, Her-2-positive, breast cancer patients. Cancer Gene Therapy (2006) 13, 958-968.
Introduction
With approximately 185 000 new cases/year, breast cancer is the second leading cause of cancer-related death in the United States and its incidence is on the rise. Gene amplification of anti-human epidermal growth factor receptor-2 (Her-2)/neu is observed in 25-30% of primary human breast cancers and 8-11% of ovarian cancers; it correlates with the pathogenesis and progression of human breast cancer and with poor prognosis.
1,2 The Her-2/neu oncogene is a member of the erbB-like oncogene family related to the epidermal growth factor receptor (EGFR). In normal biological systems, Her-2 functions as a co-receptor for various EGF-like ligands, which bind and activate other Her family members; yet, the ligand for Her-2/neu is still unknown. Her-2 overexpression and constitutive activation are observed in the most aggressive subset of breast cancers. Specific targeting of these tumors can be accomplished with antibodies directed against the extracellular domain of the Her-2 protein. One of these, 4D5, has been fully humanized and is termed trastuzumab (Herceptin; Genentech, San Francisco, CA). 2, 3 Trastuzumab has been studied in Phase II and Phase III studies of women with Her-2-positive (Her-2 þ ) metastatic breast cancer (MBC), yielding significant benefits when used alone and in combination with various chemotherapeutic agents. [4] [5] [6] [7] In these studies, Herceptin has shown additive antitumor activity, and statistically significant survival benefit, and is now being integrated into the adjuvant and neoadjuvant setting. [5] [6] [7] [8] [9] [10] Trastuzumab plus taxanes is the only combination indicated for the treatment of patients with MBC whose tumors overexpress Her-2 and as a single agent in women with Her-2-overexpressing MBCs resistant to chemotherapy. Although a subset of patients treated has shown cardiotoxicity, Herceptin is a generally well-tolerated drug and side effects that are commonly seen with chemotherapy are rarely observed. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] However, Herceptin shows activity in only 30% of Her-2 þ breast cancers -the reason why only a minority of tumors respond is not known.
The novel interleukin (IL)-10 family tumor suppressor gene, melanoma differentiation-associated gene-7 (mda-7), was identified using subtraction hybridization of cDNA libraries from actively proliferating human HO-1 melanoma cells versus interferon-b and mezerein-treated HO-1 cells. 15 The level of mda-7 mRNA was dramatically decreased in metastatic human melanomas, as compared to primary and actively proliferating normal human melanocytes. 15, 16 MDA-7 encodes a novel protein of 206 amino acids with a predicted size of 23.8 kDa. [16] [17] [18] Studies using adenoviral-mediated mda-7 (Ad-mda7) have demonstrated that adenoviral-mediated overexpression of mda-7 has tumor-selective growth inhibitory, antiangiogenic and proapoptotic properties both, in vitro and in vivo. [18] [19] [20] [21] [22] [23] 38 It is now known that mda-7 activates various signaling pathways in a cell-type-specific manner, and that these pathways ultimately converge on mitochondrial destruction and induction of apoptosis. 21, 22, [24] [25] [26] [27] [28] [29] [30] However, in spite of its clear tumor-suppressive effects, the mechanisms by which Ad-mda7 induces cytotoxicity have not been fully characterized. Our group has previously demonstrated that Ad-mda7, as a single agent therapy, induces apoptosis and inhibits growth in pancreatic, lung and breast cancer cells. 25, 28, 31 Furthermore, the results of a Phase I dose-escalation clinical trial using intratumoral delivery of MDA-7 (INGN 241) in patients with advanced cancers, including breast cancer, has shown apoptotic effects in a large volume of tumor and immunoactivating events that are consistent with the pre-clinical tumor suppressor activities of MDA-7/IL-24. 32 We hypothesized that the combination of Ad-mda7 and Herceptin would result in enhanced antitumor activity and thus evaluated the combination of Herceptin with the Ad-mda7 gene drug. In this study, we demonstrate that expression of MDA-7 induces dramatic enhancement of the apoptotic and tumor-suppressing capacities of Herceptin, compared to its use as a single agent. Furthermore, we present evidence supporting the involvement of the E-cadherin and b-catenin pathways in these effects and demonstrate that the biological activity of this combination, in vivo, is consistent with its in vitro tumorsuppressing properties.
Materials and methods

Cell lines and reagents
Most of the breast cancer cell lines utilized were obtained from American Type Culture Collection (ATCC, Rockville, MD), with the exception of the Her-2-overexpressing MCF-7-Her-18, a kind gift from Dr Mien-Chie Hung (UTMDACC). The ATCC cell lines evaluated were MDA-MB-453, SKBr3, MCF-7 and T47D. We also used primary human mammary epithelium cells, obtained from Clonetics (San Diego, CA). The cells were grown in Dulbecco's modified Eagle's medium (GIBCO/BRL, Life Technologies, Grand Island, NY) and fetal bovine serum (at 5-10% final concentration, according to the supplier's recommendation). The cells were tested routinely to ensure they were free of mycoplasma, and were used in the log phase of growth. Cells were harvested with 0.125% Trypsin-1.3 mM ethylenediaminetetraacetic acid (GIBCO) using standard procedures.
Recombinant adenovirus production and Herceptin
Replication-deficient human type 5 adenovirus (Ad5) carrying the mda-7 gene was produced as described. 7 The mda-7 gene was linked to an internal cytomegalovirus immediate early (CMV-IE) promoter and followed by Simian virus 40 polyadenylation (p(A)). Ad-Luc and AdCMVp(A) (Luciferase and empty vector, respectively) were used as control viruses. Briefly, for the generation of Ad-vectors, Ad5 vectors harboring the gene cassettes were co-transfected with plasmid pJM17 18 in human embryonic kidney 293 cells to rescue recombinant Ad-mda7, Adluc and Ad-CMVp(A) viruses. Plaques were picked, virus stocks were grown and their genomes were confirmed as correct by polymerase chain reaction/restriction analysis and DNA sequencing. Viruses were propagated in 293 cells and purified by column chromatography. Clinical grade Herceptin was used in these studies (injectable format at 21 mg/ml concentration).
MDA-7 polyclonal antibodies and Western blot analysis
Recombinant MDA-7 protein was expressed in Escherichia coli and purified using a nickel-nickel nitrilotriacetate resin (Ni-NTA) agarose column. This recombinant MDA-7 protein was used to generate rabbit polyclonal that was further purified by affinity chromatography. This antibody was used in Western blot analyses at dilutions ranging from 1:5000 to 1:10 000 (from a stock of 1 mg/ml). Cell lysates from 10 5 to 10 6 cells were suspended in 500 ml of Laemmli buffer with 5% 2-mercaptoethanol, (2ME), or supernatants (1:1 mixing with Laemmli buffer þ 2ME) were obtained after cancer cells were treated with Ad-mda7 for desired length of time, followed by SDS polyacrylamide gel electrophoresis and Western blot analysis using the Super-Signal substrate for horse radish peroxidase (Pierce Inc., Rockford, IL). Other monoclonal antibodies used in the study specifically recognized E-cadherin, b-catenin, antigen-presenting cell (APC), p21, p27, b-actin (Santa Cruz Biotechnology) and b-actin (Sigma-Aldrich, St Louis, MI).
Transduction and cell proliferation studies Cancer or normal cell lines used in this study were infected with Ad-mda7 (using Ad-luc as controls) with increasing multiplicities of infection (MOIs) (0, 100, 250, 500, 1000, 2500, 5000 and 10 000 viral particles (vp)/cell). Cells were plated at 10 5 -10 6 cells/well in a six-well plate format for cell viability, protein expression or apoptosis assays. Cell viability was assessed using Trypan blue and light microscopy.
Annexin V assay
Cancer cells were also analyzed for apoptosis, using the ApoAlert Annexin V-fluorescein isothiocyanate (FITC) kit (Clontech, Palo Alto, CA). Briefly, Ad-vector-transAd-mda7 and Herceptin in Her-2 þ breast cancer D Bocangel et al duced cells (10 5 -10 6 cells total) were washed extensively in phosphate-buffered saline (PBS) and then incubated with Annexin V-FITC reagent for 30 min on ice. Cells were then washed and processed for fluorescence-activated cell sorter (FACS) analysis and fluorescent microscopy.
Cell cycle analysis with propidium iodide staining For this purpose, we evaluated DNA content by propidium iodide (PI) staining, followed by flow cytometry analysis. For identifying cells at different stages of cell cycle, vector-infected cancer cells were prepared as a single-cell suspension of 1-2 Â 10 6 cells/ml of PBS. After the cells were fixed with cold 70% ethanol for 2 h, the cells were centrifuged, the fixative decanted and cells washed 2 Â with PBS and then stained with PI at final concentration of 50 mg/ml with RNAse at 20 mg/ml in PBS. Treated cells were then evaluated by FACS analysis following standard procedures.
Immunofluorescence studies Cells growing in chamber slides (Nunc) were treated with the respective vectors and, 48 h later, analyzed for protein expression. Cells were fixed with ethanol:acetic acid (9.5:0.5) and then treated with primary antibody (1 h, 41C). The cells were washed extensively with PBS and treated with secondary antibody. The slides were analyzed using a Nikon digital camera DXM1200 system.
Animal studies
Nude mice were obtained from Charles River Laboratories (Wilmington, MA) and treated according to a model described previously. 29 Briefly, estrogen pellets were injected in the posterior cervical region, and 2 days later, MCF-7-Her-18 cells were injected into the thoracic mammary fat pad (5 Â 10 6 cells/mouse). When tumors reached a volume of 100 mm 3 , the mice were divided into six treatment groups: vehicle, Ad-luc, Ad-mda7 Herceptin or a combination of these; viral vectors were injected intratumorally (2 Â 10 10 vp/weekly, for a total of 3 weeks). Tumor size was measured and recorded twice a week until being killed.
Statistical analysis
The data reported represents the means of X3 samples with s.d. Each experiment was repeated at least three times. The isobologram analysis and graphs were carried out using Calcusyn software (version 2), which performs multiple drug dose-effect calculations using the median effect methods described by T-C Chou and P Talalay (Trends Pharmacol Sci 4: 450-454). Differences in tumor size were analyzed for significance by the Student's t-test. Enhanced in vitro growth inhibitory and cytotoxic activity of Ad-mda7 and Herceptin in Her-2 þ breast cancer cells The antiproliferative effects of Ad-mda7 in various cancer cell types have been demonstrated in previous studies; [16] [17] [18] [19] [20] [21] [22] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] 36 and the relevance of these findings to the clinical setting is supported by in vivo lung and breast xenograft models. 17, 21 To corroborate that the Her-2 receptors expressed by the breast cancer cells are functional, we evaluated cell death in MDA-MB-453 and MCF-7 lines treated with increasing amounts of Herceptin (0-100 mg/ ml). The half-maximal inhibitory concentration (IC 50 ) values of Ad-mda7 and Herceptin, on Her-2 þ cells (MDA-MB-453, SkBr3) and Her-2À cells (MCF-7, T47D), were determined (data not shown). A significant and dose-dependent increase in cell death induced by Herceptin was observed in MDA-MB-453 (100% cell death at the two highest doses tested: 50 and 100 mg/ml).
Results
Overexpression
However, no such increase was seen in MCF-7 cells, on which the highest Herceptin dose tested induced 25-30% cell death (Figure 1b) . The IC 50 of MDA-MB-453 for Herceptin is approximately 10 mg/ml (Figure 1c) , whereas that for Her-2À MCF-7 cells was 420-fold higher. In order to evaluate combinatorial effects and interactions between both agents, we used low doses of Herceptin and Ad-mda7 (in the IC 10 -IC 20 range) for each reagent. We then performed combination experiments with Ad-mda7 and Herceptin, in MDA-MB-453 and SkBr3 (Her-2 þ ), MCF-7 and T47D (Her-2À) cells, and cell viability was monitored 72 h post-transduction using Trypan blue exclusion assays. Adenovirus-mediated expression of MDA-7 in Her-2 þ cells induced supra-additive sensitization to Herceptin treatment, and a significant decrease in cell viability (Figure 1a) . These results were further corroborated using increasing doses of Herceptin and of Ad-mda7 (Figure 2a) . To demonstrate that the observed effects were due to ectopic expression of MDA-7, MCF-7 and T47D cells were treated with Ad-luc and Herceptin; our results showed no evidence of additive or synergistic effects ( Figure 1a) . Importantly, Ad-mda7 -used as a single agent -was able to induce cell death in Her-2 þ and Her-2À breast cancer cells -dose-dependently (Figure 2a ). Ad-mda7 and Herceptin in Her-2 þ breast cancer D Bocangel et al Enhancement of apoptosis in Her-2 þ cells in vitro using a combination of Ad-mda7 and Herceptin We have previously shown that Ad-mda7 is able to rapidly induce apoptosis in various cancer cell lines, cell death being evident as early as 12 h post-transduction. 18, 22, 24 Here we evaluated the cytotoxic effects of Herceptin in breast cancer cells, using Annexin V staining, as a single agent and in combination with Ad-mda7. Treatment with Herceptin induced low-level apoptosis in Her-2 þ but not in Her-2À cells (Figure 2b ). Ad-mda7 induced apoptosis in both, Her-2 þ and Her-2À cells, independently of Her-2/neu receptor expression, when used as a single agent (30 and 20%, respectively). When used in combination with Herceptin, the levels of apoptosis dramatically increased to 450% in Her-2 þ cells, but were not significantly different from those induced by Ad-mda7 in Her-2À cells (Figure 2b ). Treatment with Ad-luc did not induce apoptosis, and the combination of Ad-luc þ Herceptin yielded signals that were comparable to those obtained with Herceptin as a single agent. To further corroborate the significance of these findings, we treated both cell lines with a combination of the two agents and determined the degree of cell death using a wide dose range for Herceptin (0-10 mg/ml) and adenovirus (0-5000 vp/cell). Treatment of MDA-MB-453 cells with increasing doses of Ad-mda7 induced dosedependent increases in cell death, most noticeable at or above 500 vp/cell (40-90%). When combined with increasing doses of Herceptin, we observed significant enhancement of the toxicity of Ad-mda7, in a dosedependent manner (Figure 3a) . For example, when used as single agents Ad-mda7 (MOI 200 vp/cell), and Herceptin (1 mg/ml), induce 10 and 20% cell death, respectively, in MDA-MB-453 cells; when used in combination (at these same doses), they induce 60% cell death. Treatment of this cell line with similar doses of Ad-luc did not demonstrate enhanced cell killing with Herceptin ( Figure 3b) . We then treated Her-2À (MCF-7) cells, with Ad-mda7, at similar doses; although there is a dosedependent increase in cell death, no further enhancement of the effect was observed in these cells with increasing doses of Herceptin (Figure 3c ). Statistical analysis of these results, and isobologram diagrams confirmed that the sensitization observed in these cells is specific to Her-2 þ cells (MDA-MB-453) and is, indeed, a synergistic effect (Figure 3d ). Isobologram analysis demonstrated synergistic interactions. Isobologram analysis and graphs were obtained using Calcusyn software, which performs drug dose-effect calculations using the median effect method described by T-C Chou et al. The graph summarizes the results of a total of seven Herceptin doses, tested at seven different Ad-mda7 doses, in triplicates (a total of 147 data points).
Ad Our results show that Her-2 expression levels in UT cells were similar to those of Ad-mda7-or Ad-luc-treated cells.
As expected, MDA-MB-453 and SkBr3 had inherently high levels of Her-2 þ cells (40 and 60%, respectively), whereas T47D and MCF-7 had low percentages (o10%) similar to those of the control cell line, A549. Expression of Her-2/neu did not significantly change upon treatment with Ad-mda7 in any of the cell lines tested (Figure 4a ). The effects of Ad-mda7 and Herceptin in MDA-MB-453 (Her-2 þ ) and MCF-7 (Her-2À) cell cycle progression, used as a single agent or in combination with Admda7, were then evaluated using PI staining and flow cytometry. When treated with Herceptin, Her-2 þ cells underwent a decrease in the number of cells in the Sphase, and increased the number of cells in G0/G1 phase (Figure 4b ). Ad-mda7 treatment caused an increase in the percentage of cells in G2 (G2/M block) in both Her-2 þ and Her-2À cells, although to different degrees (34 and 22%, from 12 and 10% of their UT controls, respectively), and induced increases in the number of apoptotic cells (sub-G0/G1, data not shown). In contrast, the vector encoding for the expression of Luciferase (Ad-luc) did not induce such effects. The combination of Admda7 þ Herceptin caused even greater increases in the number of cells in G2/M, in a supra-additive manner, and was selective for Her-2 þ cells, as indicated by the substantial decrease in the percentage of cells in the Sphase (to 12%) and an increase in the percentage of cells in G2 (68%) and sub-G0/G1 (Figure 3b and data not shown). To further investigate these phenomena, we determined the levels of proteins involved in the regulation of G2/M cell cycle progression. Progression of all eucaryotic cells into the M-phase of the cell cycle is regulated by activation of cdc2 kinase. The critical regulatory step for cdc2 activation is the dephosphorylation of tyrosine 15 and threonine 14, the former is carried out by the phosphatase cdc25. Western analysis of serine 216-phosphorylated cdc25 (S216 phospho-cdc25) using a phospho-specific antibody detected a specific 60 kDa band in Ad-mda7-treated cells, which was absent from lysates of UT, Ad-luc-or Herceptin-treated cells (Figure 4c ). Treatment with the combination Admda7 þ Herceptin yielded a greater amount of S216 phospho-cdc25 than Ad-mda7 alone. We then probed these lysates for tyrosine 15-phosphorylated cdc2 (Y15 phospho-cdc2) and detected a 34 kDa band, present at significant levels in all lysates. Treatment of Her-2 þ cells with Ad-mda7, as a single agent and in combination with Herceptin, induced decreases in Y15 phospho-cdc2, the latter greater than the former (Figure 4c Ad-mda7 and Herceptin in Her-2 þ breast cancer D Bocangel et al G2/M arrest specific to Her-2 þ cells upon treatment with Ad-mda7, and of a supra-additive effect when these cells are treated with the combination Ad-mda7 þ Herceptin.
Mechanistic studies using Ad-mda7 þ Herceptin involve the E-cadherin and b-catenin pathway We evaluated a variety of molecular effectors that could be involved in Ad-mda7 þ Herceptin-induced cytotoxicity. Western analysis of MDA-MB-453 (Her-2 þ ) cell lysates treated with Ad-mda7, Ad-luc, Herceptin or a combination of these corroborated that strong expression of MDA-7 is specific to Ad-mda7-transduced cells, and that expression of MDA-7 was absent in UT, Ad-luc-or Herceptin-treated cells (Figure 4d ). MDA-7 protein expression correlated with cell death in breast cancer tumor cells, regardless of Her-2 status, and Herceptin treatment did not increase steady-state levels of MDA-7.
Our group previously reported that MDA-7 expression in lung cancer cells and in transformed mouse embryonic fibroblasts upregulates and phosphorylates the doublestranded RNA-dependent protein kinase (PKR). Furthermore, PKR function is necessary for MDA-7-induced apoptosis as PKRÀ/À cells were unable to undergo apoptosis. 26 Expression of MDA-7 in breast cancer cells also induced significant increases in steady-state protein levels of PKR, in both Her-2 þ (MDA-MB-453) and Her-2À (MCF-7) cells. A greater increase in PKR, after treatment with a combination of the two agents, was observed in Her-2 þ cells; no such effect was noticeable in Her-2À cells. Thus, PKR upregulation in breast cancer cells correlates with increased cell death and apoptosis. Although Herceptin does not directly upregulate PKR, it potentiates MDA-7-mediated PKR expression.
In a previous report, we showed redistribution of b-catenin in lung and breast cancer cell cultures from the nucleus to the plasma membrane after Ad-mda7 transduction, whereas in UT or Ad-luc-treated tumor cells b-catenin was dispersed throughout the cytosolic and nuclear compartments. 24 Here, we investigate further b-catenin expression changes after treatment with Ad-mda7 þ Herceptin using immunocytochemical analysis. Immunocytochemical analysis after Ad-mda7 treatment confirmed the relocation of b-catenin to the plasma membrane, with no observable changes in the control treated cells (Figure 5a and data not shown). Further enhancement of this relocation was observed when Admda7 was used in combination with Herceptin (Figure 5a ). MCF-7 cells also underwent b-catenin relocation after transduction with Ad-mda7, but no further enhancement was noticeable after the combination treatment (data not shown).
We then evaluated expression of E-cadherin as a binding partner of b-catenin. Cadherins are a superfamily of transmembrane glycoproteins that mediate calciumdependent homophilic cell-cell adhesion. E-cadherin is downregulated in various cancers and its loss can lead to increased expression of MMP9 and cellular invasion. 35, 36 Integrin-b4 is another membrane protein involved in cellcell adhesion, with key roles in assembly and adhesive functions of the hemidesmosome. Both are adhesionrelated transmembrane proteins, whose expression is regulated by MDA-7. Flow cytometry analysis of cells treated with both, Ad-mda7 and Herceptin, revealed that the relocation of b-catenin correlates with specific increases in the total number of E-cadherin-positive cells (Figure 5b, left panel) . Flow cytometry analysis showed an increase in the number of E-cadherin-expressing Her-2 þ (MDA-MB-453) cells after treatment with Herceptin or Ad-mda7 individually; a dramatically greater increase was observed when Herceptin was used in combination with Ad-mda7. Her-2À (MCF-7) cells did not show increases of E-cadherin expression after the combination treatment, although a small increase in the percent of positive cells is observed over the UT control after treatment with Herceptin (Figure 5b, left panel) . Analysis of cell surface integrin-b4 revealed a dramatic increase in both cell lines after treatment with Ad-mda7 as a single agent, but after treatment with the combination of both agents, the number of integrin-b4-positive cells decreased to levels comparable to those of Ad-luc-transduced cells (Figure 5b, right panel) . These results indicate that the combination of Herceptin and MDA-7 does not cause a generalized increase in membrane protein expression, but appears to regulate specifically the catenin-cadherin signaling pathways.
Ad-mda7 has been previously reported to inhibit expression of proto-oncogenes of the phosphatidylinositol-3 kinase (PI3K) pathway in pancreatic and lung cancer cells. 24, 31 Among these is Akt; ectopic expression of MDA-7 in Her-2-overexpressing breast cancer cells significantly decreases levels of Akt and phosphorylated Akt (p-Akt). 28 We thus investigated changes in phospholipase C-g (PLC-g), glycogen synthase kinase 3b (GSK-b), APC and Bcl-2 family members Bcl-2 and Bax in our model system. Although all of these critical signaling molecules were regulated by Ad-mda7 or Herceptin treatments individually, none of these molecules were regulated synergistically upon treatment with the combination of both agents (data not shown). Taken together, our results specifically implicate the b-catenin and Ecadherin pathways in these synergistic effects.
Effects of Ad-p53 þ Herceptin in Her-2 þ and Her-2À breast cancer cells We wished to evaluate the effect of other proapoptotic, gene therapy agents in combination with Herceptin, to determine the specificity of the effects induced by Admda7. We chose Ad-p53, because it is known to trigger apoptosis specifically in tumor cells, and because the cytotoxic effects of Ad-mda7 have been shown to be independent of p53 protein expression. [16] [17] [18] [19] MDA-MB-453 (Her-2 þ ) and MCF-7 (Her-2À) cells were treated with Ad-p53, used as a single agent or in combination with increasing doses of Herceptin (1 and 2 mg/ml). Parallel cultures, treated with Ad-luc or not treated at all, were used as controls. The results of Trypan blue staining and cell counts show that Herceptin, as a single agent, induces cell death in approximately 30% of Her-2 þ cells, no such increases were observed in Her-2À cells. Ad-p53 causes a greater increase in the percent Ad-mda7 and Herceptin in Her-2 þ breast cancer D Bocangel et al cell death than Herceptin in both MDA-MB-453 and MCF-7 cells (65 and 50%, respectively), when used as a single agent (Figure 5c ). However, no significant enhancement of cell death is observed, for either cell line, after combined treatment with Herceptin at any of the two doses tested. As predicted, Herceptin demonstrated cytotoxicity only against MB-453 Her-2 þ cells; no enhancement of cytotoxicity was observed when the two agents were used in combination (Figure 5c ). Thus, the synergistic activity observed between Herceptin and Admda7 is not observed with other proapoptotic agents, such as Ad-p53.
Growth inhibitory effect of the combination Ad-mda7 þ Herceptin, in vivo To further investigate the relevance of our findings in vivo, we wished to establish tumor xenografts of the above breast cancer cell lines; unfortunately, these lines do not form tumors in nude mice. We modified our animal model to take advantage of a MCF-7-derived cell line that overexpresses Her-2 receptors, MCF-7-Her-18; this protocol has been described previously in greater detail. 28 These cells were injected into nude mice and allowed to form tumors. When the tumors reached 100 mm 3 , the animals were separated into the different treatment Ad-mda7 and Herceptin in Her-2 þ breast cancer D Bocangel et al groups: Herceptin, Ad-mda7, Ad-luc as single agents and in combination. A PBS-treated group was used as a control. Our results indicate rapid growth of the tumors treated with PBS, followed by those treated with Ad-luc; growth in the former was first noticeable at day 5, whereas the latter was first observed at day 7 ( Figure 6 ). Maximum tumor volumes for these tumors were in the ranges of 800 and 600 mm . Individual treatment with Admda7 or Herceptin produced robust antitumor effects. These results demonstrate a supra-additive effect, in vivo, of the combination Ad-mda7 þ Herceptin, compared to treatment with the single agents. Treatment with Ad-mda7 or Herceptin individually caused a reduction in tumor growth rate; however, the combination resulted in the lack of significant tumor growth for almost 20 days. Time to tumor doubling is a useful surrogate for antitumor efficacy; for the PBS and Ad-luc controls, time to tumor doubling was 6 and 13 days, respectively, and combining Ad-luc and Herceptin extended this to 14 days. Individually, Herceptin and Ad-mda7 increased this value to 16 and 22 days; however, the combination of Ad-mda7 and Herceptin resulted in a tumor growth delay of 29 days.
Discussion
Amplification of Her-2/neu proto-oncogene or oncoprotein overexpression induces a pattern of consistent genetic alterations in target human cells and is an important prognostic and predictive factor for breast cancer resistance to endocrine or adjuvant chemotherapy. 13, 14 Single agent antitumor activity of Herceptin (Trastuzumab) has been demonstrated in preclinical and clinical studies. Although this agent is only active in a minority (30%) of Her-2 þ tumors, treatments that enhance the activity of Herceptin should improve therapeutic outcome for a greater number of Her-2 þ patients. [5] [6] [7] [8] [9] [10] In this study, we have used the novel approach of combining a gene drug (Ad-mda7) with the biological agent, Herceptin, and evaluated its antitumor effects against breast cancer cells. Preliminary results of this study have been reported. 28 The synergy between the two drugs, dose dependency and specificity of the effect to Her-2 þ cells is evident (Figures 1-4) . The cell cycle analyses, shown in Figure 4b , indicate that Herceptin changes the percentage of Her-2 þ cells in S and G1 (decreasing the former, and increasing the latter), suggestive of G1 arrest. On the other hand, Ad-mda7, when used as a single agent, induces a G2/M block. The combination of the two doubles the effect of Ad-mda7 on G2/M block, and further decreases the sub-population in the S-phase; these changes are supra-additive, and specific to Her-2 þ cells (Figure 4b) .
Given the heterogeneity of cancer cells, even within the same tumor, and because these agents appear to target different intracellular signaling pathways, the combination of Ad-mda7 and Herceptin is attractive from a clinical point of view. The synergistic enhancement of the cytotoxicity induced by these agents, and its specificity to the most aggressive type of breast cancer cells (Her-2 þ ), is especially promising. We have sought to decipher the molecular mechanisms by which the combination of these two agents results in synergy. Evaluation of Her-2 levels in these cell lines, after Ad-mda7 treatment, leads us to conclude that Ad-mda7 does not act simply by upregulation of the Her-2 receptor (Figures 1b and 4a) . We have evaluated various members of the Bcl-2, PI3K and Ad-mda7 and Herceptin in Her-2 þ breast cancer D Bocangel et al b-catenin pathways using Western blot and RNA analysis. Our results implicate b-catenin/E-cadherin, among the ones studied, as the most likely responsible for the observed synergistic effect. E-cadherin, a homotypic cell-cell adhesion molecule ubiquitously expressed on epithelial cells, is considered an active suppressor of invasion and growth in normal epithelial cells. [35] [36] [37] [38] Alterations in cell surface expression of cadherins correlate with cancer progression and molecular pathogenesis: in the majority of epithelial cancers membrane expression of E-cadherin is lost. These changes are mediated by mutational inactivation of E-cadherin or b-catenin genes, by transcriptional repression or by proteolysis of the extracellular cadherin domain. Forced expression of E-cadherin in cultured cells, and transgenic mouse models of carcinogenesis, results in impaired metastatic and invasive phenotypes. 33, 34 Here, we show that Herceptin, alone and in combination with Ad-mda7, is able to upregulate specifically E-cadherin in Her-2 þ cells, and to sequester its binding partner b-catenin to the plasma membrane (Figure 5a and b, left panel), thereby inhibiting its nuclear translocation and inhibiting b-catenin-induced transcriptional activation of cell migration and cell proliferation signals.
High levels of PLC-g correlate with decreases in GSK3b, and with cancer malignancy and progression. GSK3b, a member of the Wnt signaling pathway, plays a key role in various cellular processes including cell proliferation and embryonic development, via regulation of apoptosis and b-catenin. 39 Our studies show that Admda7, alone and in combination with Herceptin, is able to downregulate PLC-g and upregulate GSK-3b (data not shown). GSK-3b phosphorylates b-catenin and activates its ubiquitin-mediated degradation, inhibiting its translocation to the nucleus, thereby preventing cancer cell proliferation and invasiveness. To further ensure our observations reflected an MDA-7-specific effect, and were not induced by the activation of apoptosis downstream of Ad-mda7 treatment, we evaluated the combination of Adp53 plus Herceptin in the same breast cell lines. Ad-p53 was able to induce cell death in both the cell types, in a dose-dependent manner, but our results show no enhanced cytotoxicity in either Her-2 þ or Her-2À cells when using this combination.
Herceptin is a paradigm for rational development of a molecularly targeted drug, yet it is only active in approximately 30% of Her-2 þ breast cancer tumors. Our results demonstrate that the combination of Admda7 with Herceptin exhibits synergistic activity in vitro and in vivo, and may increase the potential benefits of this drug to new sub-populations of Her-2 þ patients. Our data suggest that Herceptin and Ad-mda7 signal via different pathways, but the E-cadherin/b-catenin pathway is commonly used by both agents and may hold the key to understanding the synergistic activity. Our findings underscore the potential utility of this combinatorial strategy, and warrant further investigation of this therapeutic approach in clinical studies against breast cancer.
